Table 2 Primary breast cancer and androgen receptor status
From: Androgen receptor status is highly conserved during tumor progression of breast cancer
Features | AR status n (%) | ||
|---|---|---|---|
Positive (≥1 %) | Negative (<1 %) | p-value | |
Primary BC | 307 (87.0) | 46 (13.0) | |
Metastases | 105 (86.1) | 17 (13.9) | |
Recurrences | 8 (66.7) | 4 (33.3) | |
Histological subtypes | |||
No special type (NST) | 218 (86.5) | 34 (13.5) | |
Lobular | 49 (98.0) | 1 (2.0) | |
Mucinous | 10 (83.3) | 2 (16.7) | |
Carcinoma with medullary-like features | 4 (36.4) | 7 (63.6) | |
Ductulo-lobular | 6 (100) | 0 (0) | |
Tubular | 3 (75) | 1 (25) | |
Micropapillary | 3 (100) | 0 (0) | |
Cribriform | 2 (100) | 0 (0) | |
Glycogen rich | 1 (100) | 0 (0) | |
Mixed | 12 (100) | 0 (0) | |
Grading (Nottingham) | |||
G1 | 38 (92.7) | 3 (7.3) | |
G2 | 186 (96.9) | 6 (3.1) | |
G3 | 83 (69.2) | 37 (30.8) | <0.001 |
T-category (UICC 7th edition) | |||
1 | 138 (93.2) | 10 (6.8) | |
2 | 137 (82.5) | 29 (17.5) | 0.017 |
3 | 16 (76.2) | 5 (23.8) | |
4 | 16 (88.9) | 2 (11.1) | |
N-category (UICC 7th edition) | |||
N0 | 123 (85.4) | 21 (14.6) | 0.595 |
N1mi | 18 (100.0) | 0 (0.0) | |
N1 | 87 (86.1) | 14 (13.9) | |
N2 | 21 (77.8) | 6 (22.2) | |
N3 | 21 (95.5) | 1 (0.5) | |
Estrogen receptor | |||
Positive (≥1 %) | 295 (96.7) | 10 (3.3) | <0.0001 |
Negative (<1 %) | 12 (25) | 36 (75) | |
Progesterone receptor | |||
Positive (≥1 %) | 247 (96.9) | 8 (3.1) | <0.0001 |
Negative (<1 %) | 60 (61.2) | 38 (38.8) | |
Her2 Status | |||
Positive | 34 (91.9) | 3 (8.1) | 0.585 |
Negative | 270 (86.3) | 43 (13.7) | |
Equivocal | 1 (100) | 0 (0) | |
Proliferation fraction (MIB-1) | |||
High (≥20 %) | 31 (55.4) | 25 (44.6) | <0.0001 |
Low (<20 %) | 275 (93.2) | 20 (6.8) | |
Molecular subtypes (St. Gallen 2013) | |||
Luminal A | 192 (98.5) | 3 (1.5) | <0.0001 |
Luminal B (Her2 negative) | 74 (91.4) | 7 (8.6) | |
Luminal B (Her2 positive) | 24 (100.0) | 0 (0.0) | |
Her2 | 8 (80) | 2 (20) | |
Triple negative | 4 (11.4) | 31 (88.6) | |